Next-Generation Antibody Therapeutics Market Research Report
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Next</strong>-<strong>Generation</strong> <strong>Antibody</strong> <strong>Therapeutics</strong><br />
<strong>Market</strong> (Size of $1,328 million in 2014) to<br />
Witness 44% CAGR during 2015 – 2020<br />
enquiry@psmarketresearch.com<br />
www.psmarketresearch.com
<strong>Next</strong>-<strong>Generation</strong> <strong>Antibody</strong> <strong>Therapeutics</strong> <strong>Market</strong><br />
The global next generation antibody therapeutics market was valued at<br />
$1,328.3 million in 2014 and it is expected to grow at a CAGR of about 44%<br />
during the period 2015 - 2020. The global next-generation antibody<br />
therapeutics market is growing due to increasing popularity of antibodydrug<br />
conjugate (ADC) and increasing number of collaborations for R&D in<br />
next-generation antibody therapeutics. In addition, growing prevalence of<br />
chronic diseases and increase in research and development investments by<br />
various organizations for production of improved products further<br />
encourages the growth of global next-generation antibody therapeutics<br />
market. Furthermore, increase in healthcare expenditure and technological<br />
advancements in antibody therapeutics have led to the development of<br />
more efficient antibody therapeutics, which is resulting in increased<br />
demand for next-generation antibody therapeutics.<br />
Explore <strong>Report</strong> at: https://www.psmarketresearch.com/marketanalysis/next-generation-antibody-market
<strong>Next</strong>-<strong>Generation</strong> <strong>Antibody</strong> <strong>Therapeutics</strong> <strong>Market</strong><br />
Based on technology, the Fc Engineered Antibodies market is expected to<br />
witness the highest growth (CAGR of 11%) during the forecast period.<br />
Among the therapeutic areas, the oncology segment led the global nextgeneration<br />
antibody therapeutics market in 2014, with the largest market<br />
size, but the autoimmune/inflammatory is expected to see the fastest<br />
growth of 46.4% CAGR, during the period 2015 – 2020.<br />
The information and data in the publication “Global <strong>Next</strong>-<strong>Generation</strong><br />
<strong>Antibody</strong> <strong>Therapeutics</strong> <strong>Market</strong> Size, Share, Development, Growth and<br />
Demand Forecast to 2020” represent the research and analysis of data from<br />
various primary and secondary sources. The bottom-up approach has been<br />
used to calculate the global EHR systems market by type and by therapeutic<br />
area. The market numbers for countries are obtained through top-down<br />
approach. P&S <strong>Market</strong> <strong>Research</strong> analysts and consultants interact with<br />
leading companies of the concerned domain to substantiate every single<br />
data presented in this report. The company bases its primary research on<br />
discussions with prominent professionals and analysts in the industry, aided<br />
by informed and detailed online and offline research.
<strong>Next</strong>-<strong>Generation</strong> <strong>Antibody</strong> <strong>Therapeutics</strong> <strong>Market</strong><br />
Governments of various countries are involved in taking initiatives for<br />
improving healthcare facilities, and making next-generation antibody<br />
therapeutics affordable. This is increasing the demand for next-generation<br />
antibody therapeutics. The increasing global gross domestic product (GDP)<br />
and growing healthcare expenditure have created a positive impact on the<br />
growth of the next-generation antibody therapeutics market. Also, in<br />
comparison to traditional antibodies, the next-generation antibody<br />
therapeutics is more effective in the treatment of various diseases, such as<br />
cancer, autoimmune disorders, and inflammatory diseases. This is attracting<br />
various pharmaceutical and biotechnology companies to increase their<br />
investment in the R&D of next-generation antibody therapeutics.<br />
Pre-Purchase Inquiry at: https://www.psmarketresearch.com/sendenquiry?enquiry-url=next-generation-antibody-market
<strong>Next</strong>-<strong>Generation</strong> <strong>Antibody</strong> <strong>Therapeutics</strong> <strong>Market</strong><br />
However, certain restraints such as high cost of next-generation antibody<br />
therapeutics, stringent regulatory requirements and time-consuming<br />
approval process for new drugs are hindering the market growth. North<br />
America next-generation antibody therapeutics market is expected to<br />
witness the fastest growth of CAGR 46.2% globally, during the period 2015<br />
– 2020.<br />
The key companies operating in the global next-generation antibody<br />
therapeutics market include Seattle Genetics Inc., F. Hoffmann-La Roche<br />
Ltd, ImmunoGen Inc., Pfizer Inc., Amgen Inc., Biogen, Kyowa Hakko Kirin Co.<br />
Ltd., Bristol-Myers Squibb Company, Xencor Inc., AstraZeneca PLC., Dyax<br />
Corp., Takeda Pharmaceuticals Company Limited and Bayer AG.
<strong>Next</strong>-<strong>Generation</strong> <strong>Antibody</strong> <strong>Therapeutics</strong> <strong>Market</strong><br />
Download report sample at:<br />
https://www.psmarketresearch.com/market-analysis/nextgeneration-antibody-market/report-sample
GET IN TOUCH<br />
THANK YOU!<br />
For information regarding permissions and other queries<br />
Kindly write to:<br />
enquiry@psmarketresearch.com<br />
US/Canada Toll-Free: 1-888-778-7886<br />
www.psmarketresearch.com
Change language